Dehydrocorydaline
CAS: 30045-16-0
Ref. TM-T5S2358
1mg | 56.00 € | ||
2mg | 80.00 € | ||
5mg | 109.00 € | ||
10mg | 157.00 € | ||
25mg | 257.00 € | ||
50mg | 369.00 € | ||
100mg | 549.00 € | ||
1ml*10 (DMSO) | 121.00 € |
Product Information
- Dehydrocorydalin, 13-Methylpalmatine
- 13-Methylpalmatine
- 2,3,9,10-Tetramethoxy-13-Methyl-5,6-Dihydroisoquino[3,2-A]Isoquinolinium
- 2,3,9,10-Tetramethoxy-13-Methyl-5,6-Dihydroisoquino[3,2-A]Isoquinolinium Chloride
- 2,3,9,10-Tetramethoxy-13-methyl-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium
- 5,6-Dihydro-2,3,9,10-tetramethoxy-13-methyldibenzo[a,g]quinolizinium
- 7,8,13,13a-Tetradehydro-2,3,9,10-tetramethoxy-13-methylberbinium
- Berbinium, 7,8,13,13a-tetradehydro-2,3,9,10-tetramethoxy-13-methyl-
- Brn 1556798
- Corydaline, dehydro-
- See more synonyms
- Dehydrocorydalin
- Dibenzo(a,g)quinolizinium, 5,6-dihydro-2,3,9,10-tetramethoxy-13-methyl- (9CI)
- Dibenzo[a,g]quinolizinium, 5,6-dihydro-2,3,9,10-tetramethoxy-13-methyl-
1. Dehydrocorydaline (13-Methylpalmatine) exerts anti-metastatic potential via suppression of MMPs and Bcl-2 signaling in NSC-LC cells. 2. Dehydrocorydaline stimulates p38 MAPK activation, which can enhance heterodimerization of MyoD and E proteins, thus resulting in MyoD activation and myoblast differentiation. 3. Dehydrocorydaline shows antiplatelet effects, it inhibits thrombin-induced platelet aggregation in a low dose ( IC50= 34.914 ug/mL). 4. Dehydrocorydaline has anti-inflammatory and antinociceptive effects. 5. Dehydrocorydaline inhibits MCF-7 cell proliferation by inducing apoptosis mediated by regulating Bax/Bcl-2, activating caspases as well as cleaving PARP.
Chemical properties
Technical inquiry about: TM-T5S2358 Dehydrocorydaline
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.